Neostigmine reversing neuromuscular

Inhalation anaesthetics may impair the efficacy of anticholinesterases in reversing neuromuscular blockade. Propofol does not affect the reversal of rocuronium block by neostigmine. Physostigmine pre-treatment increased propofol requirements by 20% in one study. 

An isolated case report su ests that disopyramide may oppose the effects of neostigmine used to reverse neuromuscular blockade with vecuronium. 

Reversal of neuromuscular blockade Adults and children, 0.2 mg for each 1 mg neostigmine or 5 mg pyridostigmine. Administer IV simultaneously. 

Neostigmine preceded by atropine to block muscarinic effects rapidly reverses muscle paralysis induced by competitive neuromuscular blockers (decurarization). 

Sacan O, Klein K, White PF Sugammadex reversal of rocuronium-induced neuromuscular blockade A comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Anesth Analg 2007 104 569. [PMID 17312210]... 

In very high doses, aminoglycosides can produce a curare-like effect with neuromuscular blockade that results in respiratory paralysis. This paralysis is usually reversible by calcium gluconate (given promptly) or neostigmine. Hypersensitivity occurs infrequently. 

Neostigmine Prostigmin Postoperative gastrointestinal and urinary atony, myasthenia gravis, reversal of neuromuscular blocking drugs... 

Respiratory acidosis enhances -tubocurarine- and pancuronium-induced neuromuscular block and opposes reversal by neostigmine. 

Since mivacurium is metabolized by plasma cholinesterase, the interaction with the reversal drugs is unpredictable. On one hand, the neuromuscular blockade is antagonized because of increased acetylcholine concentrations in the synapse. On the other hand, mivacurium concentration may be higher because of decreased plasma cholinesterase breakdown of the muscle relaxant. The former effect usually dominates clinically, and mivacurium block is reversed by neostigmine. 

Neuromuscular paralysis This side effect most often results after direct intraperitoneal or intrapleural application of large doses of aminoglycosides. The mechanism responsible is a decrease in both the release of acetylcholine from prejunctional nerve endings and the sensitivity of the postsynaptic site. Patients with myasthenia gravis are particularly at risk. Prompt administration of calcium gluconate or neostigmine can reverse the block. 

Interactions. Morphine (also pethidine and possibly other opioids) is potentiated by monoamine oxidase inhibitors. Any central nervous system depressant (including alcohol) will have additive effects. Patients recently exposed to neuromuscular blocking agents (unless this is adequately reversed, e.g. by neostigmine) are particularly at risk from the respiratory depressant effects of morphine. The effect of diuretic drugs may be reduced by release of antidiuretic hormone by morphine. Useful interactions include the potientating effect on pain relief of tricyclic antidepressants and of dexamfetamine. 

Reversal of this type of neuromuscular block can be achieved with anticholinesterase drugs, such as neostigmine, which prevent the destruction by cholinesterase of acetylcholine released at nerve endings, allow the concentration to build up and so reduce the competitive effect of a blocking agent. 

In onoesdiesie premedication, atropine, and hyoscine block the vagus and reduce mucosal secretions hyoscine also has useful sedative effects. Glycopyrronium is frequently used during anaesthetic recovery to block the muscarinic effects of neostigmine given to reverse a nondepolarising neuromuscular blockade. 

Penicillins G and V (119) have been reported to cause neuromuscular block in animal preparations, but only at exceptionally high doses. Calcium is effective in reversal. The acylaminopenicillins augment vecuronium-induced blockade (120). Possible re-curarization with piperacillin was successfully reversed by neostigmine (121). 

For tracheal intubation the usual dose is 0.1 mg/kg. When given after suxamethonium, 0.05 mg/kg is sufficient for good abdominal relaxation. Further doses of about one-quarter to one-third of the initial dose are given at intervals of 30-40 minutes to maintain relaxation. Reversal is easily achieved with neostigmine, provided there is some spontaneous return of neuromuscular transmission beforehand. If the evoked twitch height is less than 10% of the control value, there can be difficulty in reversing the blockade this apphes to aU non-depolarizing relaxants, except perhaps vecuronium and atracurium. 

Nodal rhythm can occur after injection of pancuronium. This dysrhythmia and bradycardia appear to be more common when neostigmine (plus atropine) is given for reversal of pancuronium-induced neuromuscular blockade than for reversal of D-tubocurarine or alcuro-nium (17) cholinesterase inhibition by pancuronium may contribute to the bradycardia in these circumstances. 

Ciclosporin can cause considerable prolongation of the neuromuscular paralysis induced by pancuronium (42) in one patient (and also in another given vecuronium). Reversal required both neostigmine and edrophonium. Subsequently, recurarization occurred (SEDA-14, 116). Contributing factors could have been the solvent Cremophor EL in the ciclosporin formulation (Sandimmun) and minor renal dysfunction. 

Trimetaphan and hexamethonium can potentiate D-tubo-curarine-induced block, but clinical reports clearly showing this are lacking. Tubocurarine will increase their hypotensive effect. Neostigmine could theoretically facilitate the postulated end-plate ion channel block of trimetaphan (SEDA-13, 102) (66), which would complicate reversal of neuromuscular block. 

Jones RM, Cashman JN, Casson WR, Broadbent MP. Verapamil potentiation of neuromuscular blockade failure of reversal with neostigmine but prompt reversal with edrophonium. Anesth Analg 1985 64(10) 1021-5. 

---